Voya Investment Management LLC Sells 295,886 Shares of Johnson & Johnson $JNJ

Voya Investment Management LLC cut its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 9.1% during the third quarter, Holdings Channel.com reports. The fund owned 2,959,681 shares of the company’s stock after selling 295,886 shares during the period. Johnson & Johnson accounts for approximately 0.7% of Voya Investment Management LLC’s portfolio, making the stock its 26th largest position. Voya Investment Management LLC’s holdings in Johnson & Johnson were worth $783,225,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also made changes to their positions in JNJ. CKW Financial Group grew its position in shares of Johnson & Johnson by 0.9% during the third quarter. CKW Financial Group now owns 4,269 shares of the company’s stock worth $1,104,000 after purchasing an additional 37 shares in the last quarter. Silver Coast Investments LLC lifted its holdings in Johnson & Johnson by 3.8% in the 2nd quarter. Silver Coast Investments LLC now owns 1,066 shares of the company’s stock worth $271,000 after purchasing an additional 39 shares in the last quarter. Townsend Asset Management Corp NC ADV lifted its holdings in Johnson & Johnson by 0.6% in the 2nd quarter. Townsend Asset Management Corp NC ADV now owns 6,418 shares of the company’s stock worth $1,630,000 after purchasing an additional 39 shares in the last quarter. Triumph Capital Management lifted its holdings in Johnson & Johnson by 1.6% in the 2nd quarter. Triumph Capital Management now owns 2,531 shares of the company’s stock worth $643,000 after purchasing an additional 39 shares in the last quarter. Finally, Kwmg LLC boosted its stake in Johnson & Johnson by 1.7% in the 3rd quarter. Kwmg LLC now owns 2,383 shares of the company’s stock worth $631,000 after purchasing an additional 39 shares during the period. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Down 1.5%

Shares of JNJ stock opened at $278.42 on Wednesday. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 0.44. The stock has a market capitalization of $670.23 billion, a price-to-earnings ratio of 42.18, a price-to-earnings-growth ratio of 2.79 and a beta of 0.22. Johnson & Johnson has a 12-month low of $198.53 and a 12-month high of $290.25. The stock’s 50-day moving average price is $267.31 and its 200-day moving average price is $250.38.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, beating analysts’ consensus estimates of $2.53 by $0.06. The company had revenue of $25.40 billion during the quarter, compared to analyst estimates of $25.38 billion. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The firm’s revenue was up 5.9% on a year-over-year basis. During the same period in the prior year, the company earned $2.80 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Equities research analysts predict that Johnson & Johnson will post 11.12 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be issued a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a dividend yield of 1.9%. The ex-dividend date of this dividend is Tuesday, November 24th. Johnson & Johnson’s dividend payout ratio is 81.21%.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on JNJ. Leerink Partners cut their price objective on shares of Johnson & Johnson from $276.00 to $272.00 and set an “outperform” rating for the company in a report on Wednesday, October 14th. TD Cowen reissued a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, October 20th. UBS Group set a $270.00 target price on shares of Johnson & Johnson in a report on Wednesday, October 14th. Morgan Stanley dropped their target price on shares of Johnson & Johnson from $294.00 to $292.00 and set an “overweight” rating for the company in a research report on Thursday, October 15th. Finally, Citigroup raised their target price on shares of Johnson & Johnson from $298.00 to $303.00 and gave the company a “buy” rating in a research note on Monday, October 5th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average target price of $275.92.

View Our Latest Analysis on JNJ

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Elizabeth Forminard sold 13,072 shares of the business’s stock in a transaction on Thursday, November 12th. The shares were sold at an average price of $284.39, for a total value of $3,717,546.08. Following the sale, the executive vice president owned 16,994 shares in the company, valued at approximately $4,832,923.66. The trade was a 43.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Timothy Schmid sold 33,597 shares of the company’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the sale, the executive vice president owned 25,447 shares in the company, valued at $6,991,308.78. This represents a 56.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 0.16% of the company’s stock.

Key Headlines Impacting Johnson & Johnson

Investors following JNJ have been watching these headlines:

  • Positive Sentiment: J&J’s planned acquisition of Ollin Biosciences adds a Phase 3 candidate for retinal diseases, including wet age-related macular degeneration and diabetic macular edema. The deal includes $2.2 billion upfront and up to about $1.1 billion in milestone payments; Blackstone is expected to provide $750 million toward development. UBS sees the asset as a potential growth driver beyond 2030. J&J to Boost Ophthalmology Pipeline With $2.2B Ollin Acquisition UBS on Ollin as a Growth Driver
  • Neutral Sentiment: The Ollin acquisition strengthens J&J’s ophthalmology portfolio, but its late-stage drug would enter a competitive market and still faces clinical and commercial execution risks. J&J Bets $2.2B on Ollin’s Vision Loss Drug
  • Negative Sentiment: A Louisiana appeals court upheld a multimillion-dollar mesothelioma verdict against J&J related to its talc baby powder, adding to ongoing litigation concerns. Separately, Pomerantz LLP said it is investigating claims on behalf of J&J investors; an investigation is not a finding of wrongdoing, but may add uncertainty. Louisiana Appeals Court Upholds Damages in Mesothelioma Case Pomerantz Investor Alert

About Johnson & Johnson

(Free Report)

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.

Recommended Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.